Stress-induced hemodynamic and hemostatic changes in patients with systemic hypertension: effect of verapamil

O C Gebara1, A H Jimenez, C McKenna

  • 1Institute for Prevention of Cardiovascular Disease, Deaconess Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Clinical Cardiology
|March 1, 1996
PubMed

Insights

Sustained-release verapamil reduced harmful stress responses in hypertensive patients. The medication blunted increases in blood pressure and platelet activity, potentially lowering cardiovascular event risk.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Hypertension Research

Background:

  • Stress can trigger acute cardiovascular events like myocardial infarction through hemodynamic and hemostatic changes.
  • Atherosclerotic plaque disruption and thrombosis are critical in stress-induced cardiac events.

Purpose of the Study:

  • To evaluate hemodynamic and hemostatic responses to three stressors (posture, mental stress, cold pressor test).
  • To determine if sustained-release verapamil modifies these stress responses in hypertensive patients.

Main Methods:

  • A randomized, double-blind, placebo-controlled crossover trial involving 13 mild-to-moderate hypertension patients.
  • Patients were assessed after 4 weeks of verapamil or placebo, undergoing postural changes, mental stress, and cold pressor tests.
  • Hemodynamic (blood pressure, heart rate) and hemostatic (platelet aggregability) parameters were measured.

Main Results:

  • Stress increased systolic pressure, heart rate, and platelet aggregability during placebo.
  • Verapamil lowered baseline and post-stress blood pressure but did not change the absolute stress-induced increase.
  • Verapamil prevented stress-induced increases in platelet reactivity and reduced responses to epinephrine and collagen.

Conclusions:

  • Once-daily sustained-release verapamil blunted potentially harmful stress-induced hemodynamic and hemostatic changes in hypertensive patients.
  • Verapamil's effects on platelet reactivity suggest a mechanism for reducing cardiovascular event risk.
  • Further research is needed to confirm if these blunted responses translate to a lower incidence of acute cardiovascular events.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...